Patients Previously Treated With a Regimen Containing:
No Cirrhosis
Compensated Cirrhosis (Child-Pugh A)
1
An NS5A inhibitor1 without prior treatment with an NS3/4A protease inhibitor (PI)
16 weeks
16 weeks
An NS3/4A PI2 without prior treatment with an NS5A inhibitor
12 weeks
12 weeks
1, 2, 4, 5, or 6
PRS3
8 weeks
12 weeks
3
PRS3
16 weeks
16 weeks
* Treated with prior regimens containing ledipasvir and sofosbuvir or daclatasvir with (peg) interferon and ribavirin.
* Treated with prior regimens containing simeprevir and sofosbuvir, or simeprevir, boceprevir, or telaprevir with (peg) interferon and ribavirin.
* PRS=Prior treatment experience with regimens containing (peg) interferon, ribavirin, and/or sofosbuvir, but no prior treatment experience with an HCV NS3/4A PI or NS5A inhibitor.
* Recommended dosage in adults: Three tablets taken at the same time orally once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg) with food.
* Recommended dosage in pediatric patients 3 years and older: ◦ Pediatric Patients 3 Years to Less than 12 Years Old: Dosing is based on weight. Refer to Table 3 of the full prescribing information for specific dosing guidelines based on body weight. Instructions for Use should be followed for preparation and administration of MAVYRET oral pellets. ◦ Pediatric Patients 12 Years of Age and Older, or Pediatric Patients Weighing at Least 45 kg: three tablets taken at the same time orally once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg) with food.
* HCV/HIV-1 co-infection and patients with any degree of renal impairment: Follow the dosage recommendations in the tables above.
* Liver or Kidney Transplant Recipients: MAVYRET is recommended for 12 weeks in patients 3 years and older who are liver or kidney transplant recipients. A 16-week treatment duration is recommended in genotype 1-infected patients who are NS5A inhibitor-experienced without prior treatment with an NS3/4A PI or in genotype 3-infected patients who are PRS treatment-experienced.
Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance
How to sign up
Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
ASK PATIENT TO: Open Camera on Phone Scan QR Code & Tap Link
Learn More
Other resources brands publish to help support patients and caregivers.
Other resources
Learn More
Other resources brands publish to help support patients.
people also ask
Mavyret FAQs
How is the dosage of Mavyret?Mavyret is available in 2 dosages, including 100-40 mg Tab and 50-20 mg Pellet
What does Mavyret treat?Mavyret treats
What is Mavyret made of?Mavyret contains glecaprevir / pibrentasvir which is a Hepatitis C Virus NS3/4A Protease Inhibitor
How Is Mavyret Administered?Mavyret is administered as a Oral Pill or Oral Pellet
What Are The Mavyret Mechanism Of Action?Mavyret mechanism of action is Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 1A2 Inhibitors, Cytochrome P450 3A Inhibitors, HCV NS3/4A Protease Inhibitors, Organic Anion Transporting Polypeptide 1B1 Inhibitors, Organic Anion Transporting Polypeptide 1B3 Inhibitors, P-Glycoprotein Inhibitors or UGT1A1 Inhibitors
FAQ Data Source
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available